Waverley Pharma Inc. WAVE.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -4.69% | 47.07% | 183.68% | 1,959.58% | 729.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.69% | 47.07% | 183.68% | 1,959.58% | 729.98% |
| Cost of Revenue | 11.72% | 56.81% | 219.81% | 740.70% | 304.88% |
| Gross Profit | -26.19% | 33.25% | 139.62% | 1,784.13% | 2,301.14% |
| SG&A Expenses | 38.24% | 40.04% | 28.52% | 18.56% | -24.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.22% | 12.72% | 25.22% | 37.30% | 9.75% |
| Operating Income | -63.83% | 31.37% | 60.11% | 75.62% | 73.38% |
| Income Before Tax | -84.14% | 13.36% | 48.42% | 83.82% | 82.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.55% | 13.13% | 48.24% | 83.75% | 82.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.55% | 13.13% | 48.24% | 83.75% | 82.41% |
| EBIT | -63.83% | 31.37% | 60.11% | 75.62% | 73.38% |
| EBITDA | -69.09% | 30.69% | 60.83% | 77.16% | 70.07% |
| EPS Basic | -80.00% | 14.29% | 48.06% | 83.44% | 82.14% |
| Normalized Basic EPS | -87.88% | 13.33% | 48.75% | 72.22% | 70.54% |
| EPS Diluted | -8.79% | 47.50% | 64.92% | 86.26% | 75.14% |
| Normalized Diluted EPS | -87.88% | 13.33% | 48.75% | 72.22% | 70.54% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |